Delaney C P, Thomson A W, Demetris A J, Starzl T E
Pittsburgh Transplantation Institute, University of Pittsburgh Health Science Centre, PA 15261, USA.
Ther Immunol. 1994 Jun;1(3):153-64.
The successful results seen after organ transplantation are largely attributable to the potency and specificity of modern immunosuppressive agents. Although drug-free unresponsiveness to graft alloantigens has not been routinely achieved in clinical practice, recent appreciation of the importance of cell chimerism, which develops after the migration from donor to host of leukocytes contained in solid organ grafts, has introduced a concept which may explain the mechanism of graft tolerance. Recent evidence has indicated that immunosuppressive drugs may have a common potential to induce graft tolerance, even though they act through diverse mechanisms, and that this potential may be mediated by a permissive effect on the migration and survival of donor-derived leukocytes. This review briefly examines the mechanisms by which immunosuppressive drugs function and analyses the different methods which these agents might use to induce chimerism associated with graft tolerance. Furthermore, we describe ongoing clinical studies in which the chimerism produced after solid organ transplantation is augmented with donor bone marrow in an attempt to facilitate the induction of tolerance.
器官移植后取得的成功结果很大程度上归因于现代免疫抑制剂的效力和特异性。尽管在临床实践中尚未常规实现对移植物同种异体抗原的无药反应性,但最近对细胞嵌合体重要性的认识,这种嵌合体在实体器官移植物中所含白细胞从供体迁移到宿主后形成,引入了一个可能解释移植物耐受机制的概念。最近的证据表明,免疫抑制药物可能具有诱导移植物耐受的共同潜力,即使它们通过不同机制起作用,并且这种潜力可能由对供体来源白细胞迁移和存活的允许作用介导。本文简要探讨免疫抑制药物发挥作用的机制,并分析这些药物可能用于诱导与移植物耐受相关的嵌合体的不同方法。此外,我们描述了正在进行的临床研究,其中实体器官移植后产生的嵌合体通过供体骨髓增强,试图促进耐受的诱导。